Cargando…
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or resistance. While generally well tolerated, das...
Autores principales: | Hughes, Timothy P., Laneuville, Pierre, Rousselot, Philippe, Snyder, David S., Rea, Delphine, Shah, Neil P., Paar, David, Abruzzese, Elisabetta, Hochhaus, Andreas, Lipton, Jeffrey H., Cortes, Jorge E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312029/ https://www.ncbi.nlm.nih.gov/pubmed/30093398 http://dx.doi.org/10.3324/haematol.2018.188987 |
Ejemplares similares
-
Dasatinib induced pleural effusions - Reply
por: AJ Abdulla, Mohammad, et al.
Publicado: (2020) -
Dasatinib-Induced Pleural and Pericardial Effusions
por: Hailan, Yousef M, et al.
Publicado: (2021) -
Dasatinib-Induced Bilateral Pleural Effusions
por: Rasul, Taha F, et al.
Publicado: (2022) -
Dasatinib-induced pleural effusion: Chylothorax, an option to consider
por: Ferreiro, Lucía, et al.
Publicado: (2016) -
Dasatinib: Chylothorax and right pleural effusion: case report
Publicado: (2019)